Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).
Authors
Linda Wu
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;
Linda Wu , Claudia A.M. Fulgenzi , Antonio D'Alessio , Hong Jae Chon , Masatoshi Kudo , Martin Schönlein , Johann von Felden , Brooke Wietharn , Samuel Phen , Bernhard Scheiner , Lorenz Balcar , Yi-Hsiang Huang , Tiziana Pressiani , Gianluca Masi , Abdul Rafeh Naqash , Dominik Bettinger , Arndt Vogel , Peter R Galle , Vince Gaillard , Celina Ang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 504)
DOI
10.1200/JCO.2023.41.4_suppl.504
Abstract #
504
Poster Bd #
A14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction–associated steatotic liver disease.
First Author: Hirokazu Takahashi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.
First Author: David Cosgrove
Poster
2023 ASCO Annual Meeting
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
First Author: Masatoshi Kudo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.
First Author: Jay Parekh